WX [WuXi PharmaTech (Cayman)] 6-K: WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 PRESS RELEASE DATED AUGUST 10, 2011]
CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)
[FORM 10-Q (Mark One) x June 30, 2011 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) (Issuer's telephone number, including area code)] [AMENDED AND RESTATED BYLAWS OF CHINA PHARMA HOLDINGS, INC. (Effective August 9, 2011) SECTION 1. OFFICES 1.1. Registered Office. The registered office of the corporation shall be established and maintained at 1209 Orange Street, Corporation Trust Center, Wilmington, New Castle County, Delaware 19801. 1.2. Principal Office. The principal office of the Corporation shall be located at the principal place of] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 10, 2011 -------------------------------- President and Chief Executive Officer EX-32.1 5 cphi10qex321063011.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 10, 2011 --------------------- (principal financial officer and principal accounting officer) EX-32.2 6 cphi10qex322063011.htm]
CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x June 30, 2011
[FORM 10-Q (Mark One) x June 30, 2011 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) (Issuer's telephone number, including area code)] [AMENDED AND RESTATED BYLAWS OF CHINA PHARMA HOLDINGS, INC. (Effective August 9, 2011) SECTION 1. OFFICES 1.1. Registered Office. The registered office of the corporation shall be established and maintained at 1209 Orange Street, Corporation Trust Center, Wilmington, New Castle County, Delaware 19801. 1.2. Principal Office. The principal office of the Corporation shall be located at the principal place of] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 10, 2011 -------------------------------- President and Chief Executive Officer EX-32.1 5 cphi10qex321063011.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 10, 2011 --------------------- (principal financial officer and principal accounting officer) EX-32.2 6 cphi10qex322063011.htm]
CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)
[FORM 10-Q (Mark One) x June 30, 2011 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Delaware 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86 898-6681-1730 (China)] [AMENDED AND RESTATED BYLAWS OF CHINA PHARMAS, (Effective August 9, 2011) SECTION 1. OFFICES 1.1. Registered Office. The registered office of therporation shall be established and maintained at 1209 Orange Street,rporation Trust Center, Wilmington, Newstleunty, Delaware 19801. 1.2. Principal Office. The principal office of therporation shall be located at the principal place of business of] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:August 10, 2011 -------------------------------- President and Chief Executive Officer cphi10qex321063011.htm 5 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:August 10, 2011 --------------------- (principal financial officer and principal accounting officer) cphi10qex322063011.htm 6 EX-32.2]
CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x June 30, 2011
[FORM 10-Q (Mark One) x June 30, 2011 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Delaware 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86 898-6681-1730 (China)] [AMENDED AND RESTATED BYLAWS OF CHINA PHARMAS, (Effective August 9, 2011) SECTION 1. OFFICES 1.1. Registered Office. The registered office of therporation shall be established and maintained at 1209 Orange Street,rporation Trust Center, Wilmington, Newstleunty, Delaware 19801. 1.2. Principal Office. The principal office of therporation shall be located at the principal place of business of] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:August 10, 2011 -------------------------------- President and Chief Executive Officer cphi10qex321063011.htm 5 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:August 10, 2011 --------------------- (principal financial officer and principal accounting officer) cphi10qex322063011.htm 6 EX-32.2]
WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)
[Form 6-K TABLE OF CONTENTS Page 3 4 2]
WX [WuXi PharmaTech (Cayman)] 6-K: Form 6-K TABLE OF CONTENTS Page 3 4
[Form 6-K TABLE OF CONTENTS Page 3 4 2]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Announces Management Changes -Chief Financial Officer Resigns
[Sinovac Announces Management Changes -Chief Financial Officer Resigns - -Vice President of Sinovac Named Interim Chief Financial Officer BEIJING, August 5, 2011 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the resignation of Jacob Chik Keung Ho, its Chief Financial Officer, for personal reasons. The Company has initiated an executive search for] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD. August 5]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Announces Management Changes -Chief Financial Officer Resigns - -Vice President of Sinovac Named Interim Chief Financial Officer BEIJING, August 5, 2011 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the resignation of Jacob Chik Keung Ho, its Chief Financial Officer, for personal reasons. The Company has initiated an executive search for] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China x o Form 20-F SINOVAC BIOTECH LTD. August 5]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)
[EMPLOYMENT AGREEMENT Agreement Executive Company This EMPLOYMENT AGREEMENT (this “ WHEREAS, the Company desires to employ Executive as its Chief Financial Officer on the terms and conditions as set forth hereinafter, and Executive desires to be so employed; NOW, THEREFORE, IN CONSIDERATION of the foregoing facts, the mutual covenants and agreements contained herein and other good and valuable consideration, the] [SKYSTAR APPOINTS NEW CHIEF FINANCIAL OFFICER Bing Mei to join as CFO XI'AN, CHINA – August 1, 2011 - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Mr. Mei, is a seasoned chief financial officer fluent in both English and Mandarin with over 20 years of diverse industry experience including technology services and industrial manufacturing businesses and successful track record]
